Narumi Nakagiri
Stock Analyst
(n/a)
# 4,647
Out of 4,654 analysts
10
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Narumi Nakagiri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Upgrades: Buy | $120 → $154 | $149.76 | +2.83% | 1 | Aug 16, 2024 | |
| PFE Pfizer | Upgrades: Outperform | $28 → $34 | $28.09 | +21.04% | 3 | Aug 8, 2024 | |
| JNJ Johnson & Johnson | Downgrades: Neutral | $160 → $150 | $160.13 | -6.33% | 1 | Jul 23, 2024 | |
| AMGN Amgen | Upgrades: Buy | $320 | $319.22 | +0.24% | 2 | Dec 21, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $54 | $54.32 | -0.59% | 1 | Nov 2, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $89 → $102 | $101.88 | +0.12% | 2 | Jul 7, 2022 |
Illumina
Aug 16, 2024
Upgrades: Buy
Price Target: $120 → $154
Current: $149.76
Upside: +2.83%
Pfizer
Aug 8, 2024
Upgrades: Outperform
Price Target: $28 → $34
Current: $28.09
Upside: +21.04%
Johnson & Johnson
Jul 23, 2024
Downgrades: Neutral
Price Target: $160 → $150
Current: $160.13
Upside: -6.33%
Amgen
Dec 21, 2023
Upgrades: Buy
Price Target: $320
Current: $319.22
Upside: +0.24%
Bristol-Myers Squibb Company
Nov 2, 2023
Downgrades: Neutral
Price Target: $68 → $54
Current: $54.32
Upside: -0.59%
Merck & Co.
Jul 7, 2022
Upgrades: Outperform
Price Target: $89 → $102
Current: $101.88
Upside: +0.12%